Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-457-2 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
The main components of LIMUS Sambaydestillation are N-(n-butyl) triphosphoric triamide (NBPT) and N-(n-propyl) triphosphoric triamide (NPPT).
The Australian Government has assessed NBPT in the Existing Chemical Secondary Notification Assessment Report NA/467S (February 2011) and also provided information on toxicokinetics, metabolism and distribution:
Absorption of NBPT via oral route was almost complete, as 74.39% of the given dose was considered to be absorbed. Four out of 8 rats had blood sample collected through a jugular cannula at various times after dosing (between 1 to 120 hours). Times at which peak concentrations were reached in the blood stream (tmax) in three of the four rats were within one hour of administration with a mean peak concentration (Cmax) of 80.18 μg-equi/g. No data were available on dermal or inhalation absorptions.
NBPT was distributed to most of the organs based on the data at termination. Samples from liver, mesenteric fat, kidney, carcass and spleen combined registered higher NBPT concentrations than that in blood samples. Although lung samples were not measured in the experiment, NBPT is believed to be distributed to the lungs before its elimination into air. Regarding the quantitative distributions in different organs, higher amounts of NBPT were seen in the carcass, liver and blood with minor amounts in the kidney, spleen and mesenteric fat. After 7 days, 2.92% of the given dose remained in the body. NBPT concentrations in blood samples followed a biphasic declination pattern, decreasing rapidly to less than 14% of the Cmax 24 hours after dosing and then to <5% by 168 hours. There were no data on protein binding or enterohepatic circulation of NBPT.
Two major metabolites of NBPT were separated and identified from the urine samples. One was the glucuronic acid conjugate of NBPT, the structure of which was confirmed by LC/MS. Another was confirmed to be N-(n-butyl)-thiophosphoric diamide by both LC/MS and NMR. No metabolic pathways had been investigated on the formation of CO2 which was excreted via lungs.
Elimination of NBPT from the blood stream showed a linear declination with a calculated t½ of 78 hours. After a single oral dose, 80.12% NBPT was excreted in 7 days. NBPT was mainly eliminated via expired air (as CO2), urine and faeces with averages of 35.4%, 24.4% and 8.7% of the administered dose, respectively. Some residues were recovered from cage rinses (11.7%).
Based on structural similarities between NBPT and NPPT (NPPT is one CH2 -group shorter) significant differences between NBPT and NPPT concerning toxicokinetics, metabolism and distribution are not expected.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
